Stoke Therapeutics, Inc.
STOK
$33.61
$0.631.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -23.05% | -91.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -23.05% | -91.29% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -23.05% | -91.29% | |||
| SG&A Expenses | 5.01% | 4.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.66% | -13.13% | |||
| Operating Income | -57.84% | -124.54% | |||
| Income Before Tax | -68.74% | -120.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -63.30% | -120.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -63.30% | -120.80% | |||
| EBIT | -57.84% | -124.54% | |||
| EBITDA | -58.82% | -124.04% | |||
| EPS Basic | -62.60% | -120.63% | |||
| Normalized Basic EPS | -67.99% | -120.40% | |||
| EPS Diluted | -62.60% | -121.18% | |||
| Normalized Diluted EPS | -67.99% | -120.94% | |||
| Average Basic Shares Outstanding | 0.44% | 0.85% | |||
| Average Diluted Shares Outstanding | 0.44% | -1.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||